118 results
8-K
EX-99.2
LUMO
Lumos Pharma Inc
12 Dec 22
KOL Review of Lumos Pharma’s Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients
5:20pm
these entities. Dr. Dauber received his M.D. and Master’s of Medical Sciences in Clinical Investigation from Harvard Medical School. Fernando Cassorla, M.D
8-K
EX-99.1
LUMO
Lumos Pharma Inc
30 Nov 22
Other Events
6:27pm
Sciences in Clinical Investigation from Harvard Medical School.
Fernando Cassorla, M.D., is currently Chief of Pediatric Endocrinology at the Institute
S-8
3bnof7dw
27 Aug 21
Registration of securities for employees
12:00am
8-K
EX-99.2
hqihy0
23 Aug 21
Other Events
4:43pm
8-K
EX-10.1
pxk pmjl3
30 Dec 20
Entry into a Material Definitive Agreement
4:44pm
8-K/A
296e1
1 Jun 20
Other Events
12:00am
8-K/A
EX-10.6
lq6ajxhx0foj2cqu6oj
1 Jun 20
Other Events
12:00am